DeutschNewstral
Article
Mmarketwatch.com on 2017-12-04 14:29
Seres shares drop 7% after news of FDA orphan drug designation for ulcerative colitis therapy
Related news
Philadelphia gene therapy company gets FDA Orphan Drug Designation for lead product candidatebizjournals.com- SA biotech gets FDA orphan drug designationbizjournals.com
- Cambridge's Seres targets ulcerative colitis with new drug based on gut bacteriabizjournals.com
- CEO: Seres Therapeutics 'walks into flying' with new trial in ulcerative colitisbizjournals.com
- MAbivax stock surges 9% on trial results for ulcerative colitis therapymarketwatch.com
- MProQR shares rises on FDA orphan drug designationmarketwatch.com
Sapience Therapeutics ST-36 receives orphan drug designation from FDAwestfaironline.com
FDA Talks Regenerative Medicine Advanced Therapy Designationjdsupra.com- MA new generation of ulcerative colitis drugs is in development. Will they be the blockbusters that pharma wants?3 min readmarketwatch.com
Vinegar could potentially help treat ulcerative colitiscanadafreepress.com
Can fecal transplants help with ulcerative colitis?WCAX
Signs and symptoms of ulcerative colitisMerced Sun-Star- MBeiGene drug gets 'breakthrough therapy' designation from FDAmarketwatch.com
Digital therapy program for fibromyalgia receives FDA breakthrough device designationTechCrunch- FDA grants rare pediatric disease designation to RegenxBio gene therapybizjournals.com
- MInjectable PrEP receives ‘breakthrough therapy’ designation from FDAmetroweekly.com
- Adaptimmune gets FDA designation to accelerate development of cancer therapybizjournals.com
- FDA Unveils Considerations for Rescinding Breakthrough Therapy Designationjdsupra.com
Celcuity secures FDA 'breakthrough therapy designation' for breast cancer drugStar Tribune- FDA Issues Draft Guidance on Orphan Drug Designation in Pediatric Subpopulationsjdsupra.com